Results 191 to 200 of about 650,104 (308)

Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. [PDF]

Transl Androl Urol
de Souza VPB, Barata PC.
europepmc   +1 more source

Human–Artificial Intelligence Relationships in Lacanian Perspective: Desire, Silence, and the Big Other

International Journal of Applied Psychoanalytic Studies, Volume 23, Issue 2, June 2026.
ABSTRACT This article offers a Lacanian psychoanalytic interpretation of emerging forms of human–artificial intelligence (AI) relationships, particularly emotionally responsive systems such as AI companions and AI girlfriends. It addresses the notion of “AI psychosis,” understood not as a diagnostic category but as a descriptive term for disturbances ...
Tibor A. Brečka
wiley   +1 more source

Novel Immunotherapeutic Strategies for Castration-Resistant Prostate Cancer: Mechanisms and Clinical Advances. [PDF]

Curr Issues Mol Biol
Xia X, Xia Z, Yu L.
europepmc   +1 more source

Cervical Skip Metastases and Extensive Central Venous Thrombosis as the Initial Presentation of High‐Grade Prostate Adenocarcinoma With Discordant PI‐RADS 3 Findings: A Case Report and Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Prostate cancer can initially present with cervical lymph node “skip” metastases and extensive central venous thrombosis, without pelvic or bone involvement. A PI‐RADS 3 lesion on mpMRI does not exclude high‐grade (Gleason 5 + 5 = 10) disease. Unexplained thrombosis in elderly men warrants prostate cancer investigation.
Yuchun Luo, Benhui Lai, Juncheng Huang
wiley   +1 more source

Prognostic value of PSMA PET-derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. [PDF]

Cancer Imaging
Atasever T, Babacan GB, Ekinci ÖB, Buyukkuscu A, Uslu BS, Kabaca FZY, Atcı MM, Karyagar S, Ertürk K, Çelik E.   +9 more
europepmc   +1 more source

Genetic ancestry–concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration‐resistant prostate cancer

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background The authors observed differences in response between Black and White patients with metastatic castration‐resistant prostate cancer (mCRPC) who were treated prospectively with androgen receptor pathway inhibition (ARPI) in the Abi Race and PANTHER studies.
Sean A. Piwarski, Lauren E. Howard, Morgan A. Paul, Nick Bachelder, Bonnie LaCroix, Angela Clayton, Donna Allen, Julie Kephart, Andrew J. Armstrong, Steven R. Patierno, Daniel J. George, Terry Hyslop, Jennifer A. Freedman   +12 more
wiley   +1 more source

Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Prostate cancer (PC) arising in patients with low testosterone is often more aggressive and less responsive to androgen deprivation therapy (ADT). This study evaluated whether baseline testosterone group (low vs. normal) modifies the mortality benefit of adding docetaxel to radiation therapy (RT) and ADT in nonmetastatic high‐risk ...
Johnathan Zeng, Ming‐Hui Chen, Jing Wu, Wanling Xie, Praful Ravi, Paul Nguyen, Howard Sandler, Anthony V. D’Amico   +7 more
wiley   +1 more source

Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer. [PDF]

Bioact Mater
Di J, Lee W, Xu Y, Kong H, Zhou F, Xu J, Chen X, Lao YH, Shao D, Xie X, Yao H, Tao Y, Li M.   +12 more
europepmc   +1 more source

MITF Gain‐of‐Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Prostate cancer is the most common non‐cutaneous malignancy in men and remains a leading cause of cancer‐related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN.
Paul J. Pecorin, Nyembezi Dhliwayo, Matthew Demetrious, Ludimila Cavalcante, Veronica Rodriguez‐Bravo, Josep Domingo Domenech, Thomas Westbrook   +6 more
wiley   +1 more source

Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone. [PDF]

Cardiooncology
Bryce AH, Nimke D, Young C, Shao Q, Rozario N, Kamdar P, Ivanova J, Varghese I, Touya M.   +8 more
europepmc   +1 more source